Company / R&D per Share
LENZ Therapeutics, Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.68
FY2025
5-year range
$0.68 / $30.37
FY2021-FY2025
Trend
-51.6%
vs FY2024
Sector context
#163 of 208
Health Care
What the data says
LENZ Therapeutics, Inc.'s r&d per share of $0.68 is lower than 78% of companies in the Health Care sector (FY2025). Declined from $30.37 to $0.68 over the past 2 years.
Based on SEC 10-K filings.
0.68 in FY2025 with a 5-year CAGR of -29.9%.
Declined from $30.37 to $0.68 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -20.0%
- 5-Year CAGR
- -29.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 208This company $0.68 Sector average $28.82
▼
-97.6% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 51.6% year-over-year.
- Ranks #163 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.68 | -51.6% |
| FY2024 | $1.40 | -95.4% |
| FY2023 | $30.37 | +2189.8% |
| FY2022 | $1.33 | +1.1% |
| FY2021 | $1.31 | -67.2% |
| FY2020 | $3.99 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026